Christine Petit

USPTO Granted Patents = 13 (Patent Applications = 5)

EPO Patents = 1 (Patent Applications = 6)

Average Co-Inventor Count = 5.8

ph-index = 2

Forward Citations = 16(Granted Patents)

Location History:

Bagneux, FR (1998)
Le Plessis-Robinson, FR (1999 - 2018)
Paris, FR (2020 - 2023)

Company Filing History:

Centre National De La Recherche Scientifique

patents

2 out of 23

Université Clermont Auvergne

Centre Nationale De La Recherche Scientifique

patents

6. 1 out of 1,215

The United States of America As Represented by the Department of Health

patents

7. 2 out of 832,718

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2023

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11679140 - Prevention and/or treatment of hearing loss or impairment (2023-06-20),

2. 10751385 - Prevention and/or treatment of hearing loss or impairment (2020-08-25),

3. 9868989 - Mutation within the connexin 26 gene responsible for prelingual non-syndromic deafness and method of detection (2018-01-16),

4. 9169517 - Mutation within the connexin 26 gene responsible for prelingual non-syndromic deafness and method of detection (2015-10-27),

5. 8455195 - Mutation within the connexin 26 gene responsible for prelingual non-syndromic deafness and method of detection (2013-06-04),

6. 8143000 - Mutation within the connexin 26 gene responsible for prelingual non-syndromic deafness and method of detection (2012-03-27),

7. 7258975 - Mutation within the connexin 26 gene responsible for prelingual non-syndromic deafness and method of detection (2007-08-21),

8. 6770743 - Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury (2004-08-03),

9. 6548475 - Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury (2003-04-15),

10. 6485908 - Mutation within the connexin 26 gene responsible for prelingual non-syndromic deafness and method of detection (2002-11-26),

11. 6121231 - Use of the KAL protein and treatment with the KAL protein in treatment (2000-09-19),

12. 5998147 - Mutated polynucleotide corresponding to a mutation responsible for (1999-12-07),

13. 5763166 - Gene associated with X linked Kallmann syndrome and diagnostic (1998-06-09),

Title: Christine Petit: Innovator in Auditory Research

Introduction

Christine Petit is a prominent inventor based in Le Plessis-Robinson, France. She has made significant contributions to the field of auditory research, particularly in the prevention and treatment of hearing loss and impairment. With a total of 13 patents, her work has had a profound impact on understanding and addressing auditory disorders.

Latest Patents

Among her latest patents, Christine Petit has focused on the use of gasdermin, specifically gasdermin A, B, C, D, DFNA5, and DFNB59 (or pejvakin), for modulating cellular redox homeostasis. A particularly preferred application of gasdermin is as an antioxidant. Additionally, she has developed a virally-mediated gene therapy aimed at restoring genetically-impaired auditory and vestibular functions in individuals suffering from Usher syndrome. This innovative gene therapy utilizes an AAV2/8 vector that expresses at least one USH1 gene product, preferably SANS.

Career Highlights

Christine Petit has had a distinguished career, working with esteemed institutions such as Institut Pasteur and the Centre National de la Recherche Scientifique. Her research has not only advanced scientific understanding but has also paved the way for new therapeutic approaches in hearing loss.

Collaborations

Throughout her career, Christine has collaborated with notable colleagues, including Dominique Weil and Jean-Luc Guesdon. These partnerships have further enriched her research and contributed to her success in the field.

Conclusion

Christine Petit stands out as a leading inventor in auditory research, with her innovative patents and collaborations significantly advancing the understanding and treatment of hearing impairments. Her work continues to inspire future developments in this critical area of health.

This text is generated by artificial intelligence and may not be accurate.